INDOCO REMEDIES
|
INDOCO REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 15.44 | 16.80 | 10.10 | 2.62 | -0.32 |
| CEPS(Rs) | 23.10 | 25.37 | 18.03 | 10.30 | 7.45 |
| DPS(Rs) | 2.25 | 2.25 | 1.50 | 0.30 | 0.30 |
| Book NAV/Share(Rs) | 111.51 | 98.17 | 83.45 | 73.75 | 71.69 |
| Tax Rate(%) | 26.22 | 34.57 | 29.51 | 15.59 | 68.82 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.14 | 21.17 | 17.59 | 10.92 | 7.91 |
| EBIT Margin(%) | 13.05 | 16.27 | 12.42 | 4.95 | 1.22 |
| Pre Tax Margin(%) | 11.55 | 15.35 | 10.63 | 2.58 | -0.96 |
| PAT Margin (%) | 8.53 | 10.05 | 7.49 | 2.18 | -0.30 |
| Cash Profit Margin (%) | 12.76 | 15.17 | 13.38 | 8.58 | 7.09 |
| Performance Ratios | |||||
| ROA(%) | 8.64 | 10.63 | 7.23 | 1.96 | -0.24 |
| ROE(%) | 14.72 | 18.50 | 12.85 | 3.60 | -0.43 |
| ROCE(%) | 17.48 | 23.03 | 15.67 | 5.78 | 1.23 |
| Asset Turnover(x) | 1.01 | 1.06 | 0.96 | 0.90 | 0.79 |
| Sales/Fixed Asset(x) | 1.26 | 1.28 | 1.08 | 1.07 | 1.06 |
| Working Capital/Sales(x) | 4.35 | 4.42 | 5.76 | 10.63 | 10.46 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.80 | 0.78 | 0.93 | 0.93 | 0.94 |
| Receivable days | 70.89 | 62.90 | 65.26 | 66.96 | 76.39 |
| Inventory Days | 69.62 | 64.95 | 65.58 | 64.61 | 71.01 |
| Payable days | 89.88 | 98.49 | 143.70 | 185.76 | 182.51 |
| Valuation Parameters | |||||
| PER(x) | 21.09 | 22.42 | 28.57 | 79.99 | - |
| PCE(x) | 14.09 | 14.84 | 16.00 | 20.32 | 27.20 |
| Price/Book(x) | 2.92 | 3.84 | 3.46 | 2.84 | 2.83 |
| Yield(%) | 0.69 | 0.60 | 0.52 | 0.14 | 0.15 |
| EV/Net Sales(x) | 1.98 | 2.40 | 2.34 | 1.95 | 2.20 |
| EV/Core EBITDA(x) | 11.45 | 11.21 | 12.77 | 17.14 | 25.53 |
| EV/EBIT(x) | 15.16 | 14.74 | 18.82 | 39.27 | 180.66 |
| EV/CE(x) | 1.93 | 2.34 | 2.18 | 1.74 | 1.74 |
| M Cap / Sales | 1.80 | 2.25 | 2.14 | 1.74 | 1.93 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.30 | 24.10 | 12.19 | 14.26 | -7.05 |
| Core EBITDA Growth(%) | -12.51 | 44.98 | 80.98 | 50.75 | -40.30 |
| EBIT Growth(%) | -13.12 | 62.53 | 181.36 | 365.47 | -83.62 |
| PAT Growth(%) | -8.11 | 66.37 | 285.80 | 930.49 | -107.06 |
| EPS Growth(%) | -8.11 | 66.37 | 285.80 | 930.59 | -107.05 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.31 | 0.27 | 0.34 | 0.39 | 0.45 |
| Current Ratio(x) | 1.90 | 1.67 | 1.53 | 1.23 | 1.21 |
| Quick Ratio(x) | 1.14 | 1.07 | 0.95 | 0.77 | 0.80 |
| Interest Cover(x) | 8.70 | 17.73 | 6.93 | 2.09 | 0.56 |
| Total Debt/Mcap(x) | 0.10 | 0.07 | 0.10 | 0.14 | 0.16 |
Compare Financial Ratios of peers of INDOCO REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDOCO REMEDIES | ₹3,050.9 Cr | -0.1% | -11.7% | 1.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
INDOCO REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDOCO REMEDIES | -0.1% |
-11.7% |
1.9% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
